{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:27:36Z","timestamp":1790742456868,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T00:00:00Z","timestamp":1780185600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004032","name":"Jilin University","doi-asserted-by":"publisher","award":["2025B23"],"award-info":[{"award-number":["2025B23"]}],"id":[{"id":"10.13039\/501100004032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504127"],"award-info":[{"award-number":["82504127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.phrs.2026.108276","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:31:33Z","timestamp":1780842693000},"page":"108276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CLDN6 in cancer: Biology, clinical significance, and emerging therapeutic strategies"],"prefix":"10.1016","volume":"230","author":[{"given":"Zhuo","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengshi","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6826-1085","authenticated-orcid":false,"given":"Huinan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.phrs.2026.108276_bib1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.tcb.2020.08.004","article-title":"Tight junction structure and function revisited","volume":"30","author":"Otani","year":"2020","journal-title":"Trends Cell. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108276_bib2","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202307104","article-title":"Tight junction membrane proteins regulate the mechanical resistance of the apical junctional complex","volume":"223","author":"Nguyen","year":"2024","journal-title":"J. Cell. Biol."},{"issue":"7","key":"10.1016\/j.phrs.2026.108276_bib3","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1083\/jcb.141.7.1539","article-title":"Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin","volume":"141","author":"Furuse","year":"1998","journal-title":"J. Cell. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108276_bib4","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1083\/jcb.143.2.391","article-title":"A single gene product, claudin-1 or -2, reconstitutes tight junction strands and recruits occludin in fibroblasts","volume":"143","author":"Furuse","year":"1998","journal-title":"J. Cell. Biol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108276_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/dvdy.21437","article-title":"Genetic targeting of the endoderm with claudin-6CreER","volume":"237","author":"Anderson","year":"2008","journal-title":"Dev. Dyn."},{"issue":"2","key":"10.1016\/j.phrs.2026.108276_bib6","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/dvdy.1174","article-title":"Claudin-6: a novel tight junction molecule is developmentally regulated in mouse embryonic epithelium","volume":"222","author":"Turksen","year":"2001","journal-title":"Dev. Dyn."},{"issue":"24","key":"10.1016\/j.phrs.2026.108276_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413416","article-title":"CLDN6: from traditional barrier function to emerging roles in cancers","volume":"22","author":"Qu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108276_bib8","article-title":"Identification of claudin-6 as a molecular biomarker in pan-cancer through multiple omics integrative analysis","volume":"9","author":"Zhang","year":"2021","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/PAS.0b013e31822cfa7e","article-title":"Claudin-6 is a nonspecific marker for malignant rhabdoid and other pediatric tumors","volume":"36","author":"Sullivan","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib10","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1365-2559.2012.04314.x","article-title":"Distinct expression pattern of claudin-6, a primitive phenotypic tight junction molecule, in germ cell tumours and visceral carcinomas","volume":"61","author":"Ushiku","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.phrs.2026.108276_bib11","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1051497","article-title":"The role and mechanism of claudins in cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.189019","article-title":"Finding the junction between claudins and endometrial carcinoma","volume":"1878","author":"Capoferri","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2026.108276_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e21338","article-title":"Expression patterns of claudins in cancer","volume":"9","author":"Tao","year":"2023","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12967-023-04433-8","article-title":"The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis","volume":"21","author":"Simon","year":"2023","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.phrs.2026.108276_bib15","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1007\/s11010-022-04450-z","article-title":"The expression and the tumor suppressor role of CLDN6 in colon cancer","volume":"477","author":"Qu","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib16","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s11658-024-00629-y","article-title":"CLDN6 inhibits breast cancer growth and metastasis through SREBP1-mediated RAS palmitoylation","volume":"29","author":"Jin","year":"2024","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.phrs.2026.108276_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.595436","article-title":"Association of CLDN6 and CLDN10 with immune microenvironment in ovarian cancer: a study of the claudin family","volume":"12","author":"Gao","year":"2021","journal-title":"Front. Genet."},{"issue":"12","key":"10.1016\/j.phrs.2026.108276_bib18","doi-asserted-by":"crossref","first-page":"5444","DOI":"10.7150\/ijbs.116340","article-title":"CLDN6 induces chemoresistance through protective autophagy in breast cancer","volume":"21","author":"Qu","year":"2025","journal-title":"Int. J. Biol. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010129","article-title":"CLDN6 Suppresses c-MYC-mediated aerobic glycolysis to inhibit proliferation by TAZ in breast cancer","volume":"23","author":"Qu","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108276_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110930","article-title":"CLDN6 inhibits colorectal cancer proliferation dependent on restraining p53 ubiquitination via ZO-1\/PTEN axis","volume":"112","author":"Dong","year":"2023","journal-title":"Cell. Signal."},{"issue":"5","key":"10.1016\/j.phrs.2026.108276_bib21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/cbf.3489","article-title":"Downregulation of CLDN6 inhibits cell proliferation, migration, and invasion via regulating EGFR\/AKT\/mTOR signalling pathway in hepatocellular carcinoma","volume":"38","author":"Huang","year":"2020","journal-title":"Cell. Biochem. Funct."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/CBM-201554","article-title":"Claudin-6 is down-regulated in gastric cancer and its potential pathway","volume":"28","author":"Lu","year":"2020","journal-title":"Cancer Biomark."},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060920","article-title":"The chimeric antigen receptor T cell target claudin 6 is a marker for early organ-specific epithelial progenitors and is expressed in some pediatric solid tumor entities","volume":"17","author":"Seidmann","year":"2025","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.phrs.2026.108276_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011709","article-title":"Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid\/rhabdoid brain tumors and other pediatric solid tumors","volume":"13","author":"Madsen","year":"2025","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01004-z","article-title":"Claudin-9 constitutes tight junctions of folliculo-stellate cells in the anterior pituitary gland","volume":"11","author":"Higashi","year":"2021","journal-title":"Sci. Rep."},{"issue":"18","key":"10.1016\/j.phrs.2026.108276_bib26","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.7150\/jca.55727","article-title":"The Expression of CLDN6 in hepatocellular carcinoma tissue and the effects of CLDN6 on biological phenotypes of hepatocellular carcinoma cells","volume":"12","author":"Lu","year":"2021","journal-title":"J. Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108276_bib27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s12094-022-03021-4","article-title":"Claudin-6 enhances the malignant progression of gestational trophoblastic neoplasm by promoting proliferation and metastasis","volume":"25","author":"Wu","year":"2023","journal-title":"Clin. Transl. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108276_bib28","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1111\/cas.15284","article-title":"Aberrant expression of claudin-6 contributes to malignant potentials and drug resistance of cervical adenocarcinoma","volume":"113","author":"Ito","year":"2022","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.phrs.2026.108276_bib29","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.7150\/ijbs.88539","article-title":"NK-92MI cells engineered with anti-claudin-6 chimeric antigen receptors in immunotherapy for ovarian cancer","volume":"20","author":"Li","year":"2024","journal-title":"Int. J. Biol. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2026.108276_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12102748","article-title":"Prognostic significance of aberrant claudin-6 expression in endometrial cancer","volume":"12","author":"Kojima","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.phrs.2026.108276_bib31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s10637-022-01276-w","article-title":"A phase II study assessing the safety and efficacy of ASP1650 in male patients with relapsed refractory germ cell tumors","volume":"40","author":"Adra","year":"2022","journal-title":"Invest. New. Drugs"},{"key":"10.1016\/j.phrs.2026.108276_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1193133","article-title":"Development and validation of prognostic index based on purine metabolism genes in patients with bladder cancer","volume":"10","author":"Wu","year":"2023","journal-title":"Front. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib33","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/neuonc\/noad205","article-title":"Systematic characterization of antibody-drug conjugate targets in central nervous system tumors","volume":"26","author":"Coy","year":"2024","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib34","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41419-025-07448-9","article-title":"CLDN6 triggers NRF2-mediated ferroptosis through recruiting DLG1\/PBK complex in breast cancer","volume":"16","author":"Qi","year":"2025","journal-title":"Cell. Death Dis."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib35","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13046-020-01547-5","article-title":"A SUMOylation-dependent HIF-1alpha\/CLDN6 negative feedback mitigates hypoxia-induced breast cancer metastasis","volume":"39","author":"Jia","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jbt.23682","article-title":"CLDN6 inhibited cellular biological function of nonsmall cell lung cancer cells through suppressing aerobic glycolysis via the RIP1\/ASK1\/JNK axis","volume":"38","author":"Guo","year":"2024","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.phrs.2026.108276_bib37","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/j.wneu.2021.04.005","article-title":"Effects of the tight junction protein CLDN6 on cell migration and invasion in high-grade meningioma","volume":"151","author":"Yang","year":"2021","journal-title":"World Neurosurg."},{"key":"10.1016\/j.phrs.2026.108276_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2022.153802","article-title":"The prognostic impact of Claudin 6 in papillary renal cell carcinoma","volume":"231","author":"Mikuteit","year":"2022","journal-title":"Pathol. Res. Pract."},{"issue":"4","key":"10.1016\/j.phrs.2026.108276_bib39","first-page":"403","article-title":"The role of claudin-6 in chromophobe renal cell carcinoma","volume":"38","author":"Erlmeier","year":"2023","journal-title":"Histol. Histopathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/pjp.2022.117171","article-title":"Claudin 6 is associated with a short survival and a short recurrent free interval in non-small cell lung carcinoma","volume":"73","author":"Soini","year":"2022","journal-title":"Pol. J. Pathol."},{"issue":"12","key":"10.1016\/j.phrs.2026.108276_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.105665","article-title":"Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point","volume":"25","author":"Screnci","year":"2022","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib42","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1083\/jcb.147.1.185","article-title":"Endothelial claudin: claudin-5\/TMVCF constitutes tight junction strands in endothelial cells","volume":"147","author":"Morita","year":"1999","journal-title":"J. Cell. Biol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108276_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213977","article-title":"Chromosomally unstable gastric cancers overexpressing claudin-6 disclose cross-talk between HNF1A and HNF4A, and upregulated cholesterol metabolism","volume":"23","author":"Dwivedi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib44","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10120-019-01014-x","article-title":"Claudin-6 is a single prognostic marker and functions as a tumor-promoting gene in a subgroup of intestinal type gastric cancer","volume":"23","author":"Kohmoto","year":"2020","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib45","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2967\/jnumed.124.268487","article-title":"177)Lu-labeled anticlaudin 6 monoclonal antibody for targeted therapy in esophageal cancer","volume":"66","author":"Du","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/biom14030272","article-title":"The expression of the claudin family of proteins in colorectal cancer","volume":"14","author":"Cox","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.phrs.2026.108276_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1221815","article-title":"Identification of key claudin genes associated with survival prognosis and diagnosis in colon cancer through integrated bioinformatic analysis","volume":"14","author":"Alghamdi","year":"2023","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib48","doi-asserted-by":"crossref","first-page":"367","DOI":"10.21873\/invivo.13837","article-title":"Clinicopathological significance of claudin-6 immunoreactivity in low-grade, early-stage endometrioid endometrial carcinoma","volume":"39","author":"Lee","year":"2025","journal-title":"Vivo"},{"issue":"26","key":"10.1016\/j.phrs.2026.108276_bib49","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000043110","article-title":"The prognostic and therapeutic potential of Claudin-6 and Trop-2 expression as targeted biomarkers in serous ovarian cancer: an observational study","volume":"104","author":"Yuceer","year":"2025","journal-title":"Medicine"},{"issue":"11","key":"10.1016\/j.phrs.2026.108276_bib50","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1158\/1078-0432.CCR-22-2981","article-title":"Preclinical efficacy of the antibody-drug conjugate CLDN6-23-ADC for the treatment of CLDN6-positive solid tumors","volume":"29","author":"McDermott","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108276_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110393","article-title":"CLDN6 inhibits breast cancer cell malignant behavior by suppressing ERK signaling","volume":"97","author":"Lu","year":"2022","journal-title":"Cell. Signal."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib52","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13046-023-02644-x","article-title":"CLDN6 inhibits breast cancer metastasis through WIP-dependent actin cytoskeleton-mediated autophagy","volume":"42","author":"Dong","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib53","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s10517-023-05871-6","article-title":"CLDN6 suppresses migration and invasion of MCF-7 and SKBR-3 breast cancer cells by blocking the SMAD\/Snail\/MMP-2\/9 axis","volume":"175","author":"Liu","year":"2023","journal-title":"Bull. Exp. Biol. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108276_bib54","first-page":"1590","article-title":"CLDN6-mediates SB431542 action through MMPs to regulate the invasion, migration, and EMT of breast cancer cells","volume":"13","author":"Li","year":"2020","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.phrs.2026.108276_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.120328","article-title":"KHDRBS3 promotes paclitaxel resistance and induces glycolysis through modulated MIR17HG\/CLDN6 signaling in epithelial ovarian cancer","volume":"293","author":"Wu","year":"2022","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109138","article-title":"Independent prognostic value of CLDN6 in bladder cancer based on M2 macrophages related signature","volume":"27","author":"Qi","year":"2024","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.phrs.2026.108276_bib57","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.21037\/tcr-23-19","article-title":"Downregulation of CLDN6 inhibits cell migration and invasion and promotes apoptosis by regulation of the JAK2\/STAT3 signaling pathway in hepatocellular carcinoma","volume":"12","author":"He","year":"2023","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib58","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2021.12316","article-title":"Claudin 6: therapeutic prospects for tumours, and mechanisms of expression and regulation (Review)","volume":"24","author":"Du","year":"2021","journal-title":"Mol. Med. Rep."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib59","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13046-016-0396-x","article-title":"DNA methylation of claudin-6 promotes breast cancer cell migration and invasion by recruiting MeCP2 and deacetylating H3Ac and H4Ac","volume":"35","author":"Liu","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"7517","key":"10.1016\/j.phrs.2026.108276_bib60","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Cancer Genome Atlas Research N","year":"2014","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.phrs.2026.108276_bib61","doi-asserted-by":"crossref","first-page":"688","DOI":"10.5306\/wjco.v12.i8.688","article-title":"Gastric cancer molecular classification based on immunohistochemistry and in situ hybridization: analysis in western patients after curative-intent surgery","volume":"12","author":"Ramos","year":"2021","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108276_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2024.105952","article-title":"NDMA enhances claudin-1 and -6 expression viaCYP2E1\/ROS in AGS cells","volume":"102","author":"Garcia-Garcia","year":"2025","journal-title":"Toxicol. Vitr."},{"issue":"12","key":"10.1016\/j.phrs.2026.108276_bib63","doi-asserted-by":"crossref","first-page":"11663","DOI":"10.1007\/s11033-022-07976-z","article-title":"Claudin-6 increases SNAI1, NANOG and SOX2 gene expression in human gastric adenocarcinoma AGS cells","volume":"49","author":"Medrano-Gonzalezl","year":"2022","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib64","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s12253-020-00806-2","article-title":"Tight junction-related CLDN5 and CLDN6 genes, and gap junction-related GJB6 and GJB7 genes are somatically mutated in gastric and colorectal cancers","volume":"26","author":"Son","year":"2020","journal-title":"Pathol. Oncol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64116-2","article-title":"Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI\/SNF gene alteration","volume":"14","author":"Kraemer","year":"2024","journal-title":"Sci. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108276_bib66","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1158\/1541-7786.MCR-20-0835","article-title":"Aberrant claudin-6-adhesion signaling promotes endometrial cancer progression via estrogen receptor alpha","volume":"19","author":"Kojima","year":"2021","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108276_bib67","doi-asserted-by":"crossref","DOI":"10.1111\/andr.70217","article-title":"The FUnctional Role and Molecular Characterization of the Therapeutic Target CLDN6 in germ cell tumors","author":"Zwick","year":"2026","journal-title":"Andrology"},{"key":"10.1016\/j.phrs.2026.108276_bib68","article-title":"Estrogen receptor and claudin-6 might play vital roles for long-term prognosis in patients with luminal a breast cancer who underwent neoadjuvant chemotherapy","volume":"12","author":"Liu","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib69","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaci.2023.11.018","article-title":"Engineering therapeutic monoclonal antibodies","volume":"153","author":"Stone","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib70","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41568-024-00690-x","article-title":"Cancer therapy with antibodies","volume":"24","author":"Paul","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2026.108276_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2024.101922","article-title":"Enhancing complement activation by therapeutic anti-tumor antibodies: mechanisms, strategies, and engineering approaches","volume":"77","author":"Ovcinnikovs","year":"2025","journal-title":"Semin. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108276_bib72","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br. J. Cancer"},{"issue":"10396","key":"10.1016\/j.phrs.2026.108276_bib73","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.phrs.2026.108276_bib74","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib75","doi-asserted-by":"crossref","DOI":"10.1093\/immadv\/ltae005","article-title":"Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review","volume":"5","author":"Dewaele","year":"2025","journal-title":"Immunother. Adv."},{"issue":"8","key":"10.1016\/j.phrs.2026.108276_bib76","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1080\/17460441.2025.2522088","article-title":"The impact of CD3 affinity-attenuation on T cell engaging bispecific antibodies: is it really that simple?","volume":"20","author":"Abdelmotaleb","year":"2025","journal-title":"Expert. Opin. Drug. Discov."},{"issue":"748","key":"10.1016\/j.phrs.2026.108276_bib77","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adl2720","article-title":"Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell-engaging bispecific antibody targeting human claudin 6","volume":"16","author":"Stadler","year":"2024","journal-title":"Sci. Transl. Med."},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib78","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"10","key":"10.1016\/j.phrs.2026.108276_bib79","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009563","article-title":"SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3\/CD137","volume":"12","author":"Kamikawa","year":"2024","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib80","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/2326-6066.CIR-23-0638","article-title":"Engineering CD3\/CD137 dual specificity into a DLL3-targeted T-cell engager enhances T-cell infiltration and efficacy against small-cell lung cancer","volume":"12","author":"Mikami","year":"2024","journal-title":"Cancer Immunol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2026.108276_bib81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"3","key":"10.1016\/j.phrs.2026.108276_bib82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108276_bib83","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","article-title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","volume":"29","author":"Mackensen","year":"2023","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib84","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s10020-023-00636-3","article-title":"Targeting CLDN6 in germ cell tumors by an antibody-drug-conjugate and studying therapy resistance of yolk-sac tumors to identify and screen specific therapeutic options","volume":"29","author":"Skowron","year":"2023","journal-title":"Mol. Med."},{"issue":"579","key":"10.1016\/j.phrs.2026.108276_bib85","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb6282","article-title":"Targeting tumor lineage plasticity in hepatocellular carcinoma using an anti-CLDN6 antibody-drug conjugate","volume":"13","author":"Kong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108276_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2024.105449","article-title":"Adoptive T cell therapies for solid tumors: T(I)ME is of the essence","volume":"109","author":"Amwas","year":"2024","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib87","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"22","key":"10.1016\/j.phrs.2026.108276_bib88","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"JAMA"},{"issue":"6476","key":"10.1016\/j.phrs.2026.108276_bib89","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1126\/science.aay5967","article-title":"An RNA vaccine drives expansion and efficacy of claudin-CAR-T cells against solid tumors","volume":"367","author":"Reinhard","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.phrs.2026.108276_bib90","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","article-title":"T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome","volume":"22","author":"Klebanoff","year":"2023","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib91","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib92","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.2020983","article-title":"Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer","volume":"11","author":"Matsuzaki","year":"2022","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.phrs.2026.108276_bib93","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108276_bib94","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"issue":"6","key":"10.1016\/j.phrs.2026.108276_bib95","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108276_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"issue":"7","key":"10.1016\/j.phrs.2026.108276_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012217","article-title":"Shared epitopes create safety and efficacy concerns in several cancer vaccines","volume":"13","author":"Kellermann","year":"2025","journal-title":"J. Immunother. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600191X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182600191X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T14:05:45Z","timestamp":1785074745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182600191X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":97,"alternative-id":["S104366182600191X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108276","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CLDN6 in cancer: Biology, clinical significance, and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108276"}}